Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6208-6218

  Fischer, Eliane ^a,b   Chaitanya, Krishna ^a   Wuëst, Thomas ^a   Wadle, Andreas ^a   Scott, Andrew M ^c   Van Den Broek, Maries ^a   Schibli, Roger ^b   Bauer, Stefan ^a   Renner, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST ACTIVATION PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; LUTETIUM 177; SERINE PROTEINASE; SIBROTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MIGRATION; CONFOCAL MICROSCOPY; CROSS REACTION; HUMAN; HUMAN CELL; INTERNALIZATION; MELANOMA; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING, COMPETITIVE; CELL LINE, TUMOR; EPITOPE MAPPING; FEMALE; GELATINASES; HUMANS; IMMUNOGLOBULIN G; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROTEIN TRANSPORT; RADIOIMMUNOTHERAPY; SERINE ENDOPEPTIDASES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869203157     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0644     Document Type: Article

References (39)

1. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7. (Pubitemid 39551661)
2. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918-26. (Pubitemid 351206771)
3. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63. (Pubitemid 47525152)
4. Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, et al. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology 2009;55:432-40.
5. Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 2003;120:182-8. (Pubitemid 36513065)
6. Aoyama A, Chen WT. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci U S A 1990;87: 8296-300.
7. Kelly T. Evaluation of seprase activity. Clin Exp Metastasis 1999; 17:57-62. (Pubitemid 29284565)
8. Garin-Chesa P,Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990;87:7235-9.
9. Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry (Mosc) 2008;47:1076-86.
10. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999;274:36505-12.
11. Christiansen VJ, Jackson KW, Lee KN, McKee PA. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys 2007;457:177-86. (Pubitemid 46048698)
12. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005;4:351-60. (Pubitemid 40443920)
13. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002;277:29231-41.
14. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005;42:935-45. (Pubitemid 41401132)
15. Kennedy A, Dong H, Chen D, Chen WT. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer 2009;124:27-35.
16. Mueller SC, Ghersi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M, et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem 1999;274:24947-52.
17. Wolf BB, Quan C, Tran T, Wiesmann C, Sutherlin D. On the edge of validation - cancer protease fibroblast activation protein. Mini Rev Med Chem 2008;8:719-27.
18. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011;11:245.
19. Niedermeyer J, Enenkel B, Park JE, Lenter M, Rettig WJ, Damm K, et al. Mouse fibroblast-activation protein-conserved Fap gene organization and biochemical function as a serine protease. Eur J Biochem 1998;254:650-4. (Pubitemid 28308118)
20. Huang Y, Simms AE, Mazur A, Wang S, Leon NR, Jones B, et al. Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 2011;28:567-79.
21. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010;330:827-30.
22. Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008;37:154-8.
23. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736-41. (Pubitemid 46952939)
24. Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003;26:44-8. (Pubitemid 36302438)
25. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47. (Pubitemid 36554586)
26. Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 2008;14: 4584-92.
27. Bauer S, Adrian N, Williamson B, Panousis C, Fadle N, Smerd J, et al. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol 2004;172:3930-9. (Pubitemid 38337981)
28. Bauer S, Adrian N, Fischer E, Kleber S, Stenner F, Wadle A, et al. Structure-activity profiles of Ab-derived TNF fusion proteins. J Immunol 2006;177:2423-30. (Pubitemid 44201003)
29. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999;274:18218-30.
30. Knogler K, Grünberg J, Novak-Hofer I, Zimmermann K, Schubiger PA. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol 2006;33: 883-9. (Pubitemid 44512139)
31. Fischer E, Grunberg J, Cohrs S, Hohn A, Waldner-Knogler K, Jeger S, et al. L1-CAM-targeted antibody therapy and (177) Lu-Radioimmunotherapy of disseminated ovarian cancer. Int J Cancer 2011; 130:2715-21.
32. Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012;161:422-8.
33. Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm 2011;8:2039-49.
34. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993;53:3327-35. (Pubitemid 23223305)
35. Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994;54:5702-10. (Pubitemid 24346270)
36. Fazakas C, Wilhelm I, Nagyoszi P, Farkas AE, Hasko J, Molnar J, et al. Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PloS ONE 2011;6:e20758.
37. Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, et al. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther 2003;2:729-37.
38. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994;12: 1193-203. (Pubitemid 24173933)
39. Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, et al. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol 2001;51:177-80. (Pubitemid 32216069)